Parkinson's Disease and COVID-19: Do We Need to Be More Patient?

Paulina Gonzalez-Latapi, Conor Fearon, Alfonso Fasano, Anthony E. Lang*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)277
Number of pages1
JournalMovement Disorders
Volume36
Issue number2
DOIs
StatePublished - Feb 2021

Funding

This study was supported in part by Parkinson's Canada through their support of the fellowship training of PGL. Funding agencies: P.G.L., C.L., and A.F. report no disclosures. A.E.L. has intellectual property rights with AbbVie, Acorda, AFFiRis, Biogen, Denali, Janssen, Intracellular, Kallyope, Lundbeck, Paladin, Retrophin, Roche, Sun Pharma, Theravance, and Corticobasal Degeneration Solutions; is a consultant for Jazz Pharma, PhotoPharmics, and Sunovion; is on the advisory boards of Sun Pharma, AbbVie, and Sunovion; is employed by Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; has received honoraria from the University Health Network and University of Toronto; and has received grants from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press.

Keywords

  • COVID-19
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this